Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,677 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment.
Smith EA, Belote RL, Cruz NM, Moustafa TE, Becker CA, Jiang A, Alizada S, Prokofyeva A, Chan TY, Seasor TA, Balatico M, Cortes-Sanchez E, Lum DH, Hyngstrom JR, Zeng H, Deacon DC, Grossmann AH, White RM, Zangle TA, Judson-Torres RL. Smith EA, et al. Among authors: jiang a. J Exp Clin Cancer Res. 2024 Dec 3;43(1):317. doi: 10.1186/s13046-024-03234-1. J Exp Clin Cancer Res. 2024. PMID: 39627834 Free PMC article.
Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment.
Smith EA, Belote RL, Cruz NM, Moustafa TE, Becker CA, Jiang A, Alizada S, Chan TY, Seasor TA, Balatico M, Cortes-Sanchez E, Lum DH, Hyngstrom JR, Zeng H, Deacon DC, Grossmann AH, White RM, Zangle TA, Judson-Torres RL. Smith EA, et al. Among authors: jiang a. bioRxiv [Preprint]. 2024 Jun 17:2024.06.15.599116. doi: 10.1101/2024.06.15.599116. bioRxiv. 2024. Update in: J Exp Clin Cancer Res. 2024 Dec 3;43(1):317. doi: 10.1186/s13046-024-03234-1 PMID: 38948879 Free PMC article. Updated. Preprint.
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
Traphagen NA, Schwartz GN, Tau S, Roberts AM, Jiang A, Hosford SR, Marotti JD, Goen AE, Romo BA, Johnson AL, Duffy EK, Demidenko E, Heverly P, Mosesson Y, Soucy SM, Kolling F, Miller TW. Traphagen NA, et al. Among authors: jiang a. Clin Cancer Res. 2023 Sep 15;29(18):3717-3728. doi: 10.1158/1078-0432.CCR-23-0488. Clin Cancer Res. 2023. PMID: 37439680 Free PMC article.
Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.
Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, Straussman R, Miller TW. Shee K, et al. Among authors: jiang a. FASEB J. 2019 Feb;33(2):1644-1657. doi: 10.1096/fj.201801241R. Epub 2018 Aug 30. FASEB J. 2019. PMID: 30161001 Free PMC article.
These findings highlight BMP4 and its downstream pathway activation as a therapeutic opportunity in ER(+) breast cancer.-Shee, K., Jiang, A., Varn, F. S., Liu, S., Traphagen, N. A., Owens, P., Ma, C. X., Hoog, J., Cheng, C., Golub, T. R., Straussman, R …
These findings highlight BMP4 and its downstream pathway activation as a therapeutic opportunity in ER(+) breast cancer.-Shee, K., …
Small GTPase ARF6 controls VEGFR2 trafficking and signaling in diabetic retinopathy.
Zhu W, Shi DS, Winter JM, Rich BE, Tong Z, Sorensen LK, Zhao H, Huang Y, Tai Z, Mleynek TM, Yoo JH, Dunn C, Ling J, Bergquist JA, Richards JR, Jiang A, Lesniewski LA, Hartnett ME, Ward DM, Mueller AL, Ostanin K, Thomas KR, Odelberg SJ, Li DY. Zhu W, et al. Among authors: jiang a. J Clin Invest. 2017 Dec 1;127(12):4569-4582. doi: 10.1172/JCI91770. Epub 2017 Oct 23. J Clin Invest. 2017. PMID: 29058688 Free PMC article.
1,677 results